New hope for PAH patients: early trial tests Easier-to-Use inhaled treatment
Disease control
Recruiting now
This early-stage study is testing the safety of a new inhaled medication called L608 in healthy volunteers. L608 is being developed as a longer-lasting, easier-to-use version of an existing treatment for pulmonary arterial hypertension (PAH), a serious condition affecting blood v…
Phase: PHASE1 • Sponsor: Pharmosa Biopharm Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:27 UTC